Karyopharm and Menarini Group Announce Orphan Medicinal Prod

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...

Related Keywords

United States , Norway , Australia , United Kingdom , China , Liechtenstein , Canada , Northern Ireland , Craigavon , Germany , Iceland , Israel , Singapore , Italy , South Korea , Switzerland , Turkey , America , Reshma Rangwala , Selective Inhibitor Of Nuclear Export , Linkedin , Menarini Group , Nasdaq , Committee For Orphan Medicinal Products , European Union , Head Of Medical Affairs Oncology , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Exchange Commission , Prnewswire Karyopharm Therapeutics Inc , National Organization Of Rare Diseases , European Medicines Agency , European Economic Area , Chief Medical Officer , Olivia Del Puerto , Medical Affairs Oncology , Orphan Medicinal , National Organization , Rare Diseases , Northern European , Product Characteristics , European Public Assessment Report , Selective Inhibitor , Nuclear Export , Private Securities Litigation Reform Act , Quarterly Report , Karyopharm Therapeutics , Rare Disease Database , Primary Myelofibrosis ,